OTCPK:HALB - Post by User
Post by
AveragePennyon Dec 13, 2021 11:17am
53 Views
Post# 34225033
Halberd Successfully Eradicates Interleukin-1
Halberd Successfully Eradicates Interleukin-1 Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board certified attending neurologist remarked, "Interleukin-1 is associated with many diseases, including critically life-threatening and quality of life deterioration afflictions. The ability to control the levels of IL-1 in cerebral spinal fluid gives us an effective tool in obstructing the progression of various neurological diseases, especially Alzheimer's, as well as other diseases with the same antigens and/or cytokines."
William A. Hartman, Halberd Corporation's Chairman, President & CEO, added, "We have now demonstrated that through our patented and patent pending extracorporeal laser irradiation methodology that we can eradicate targeted disease antigens and inflammatory cytokines associated with neurodegenerative diseases. We have no doubt that our technology will also be successful in eliminating the balance of the inflammatory cytokines and excitatory neurotransmitters identified in our test plan.
https://www.accesswire.com/677159/halberd-successfully-eradicates-interleukin-1-in-its-continued-progress-toward-eliminating-neurodegenerative-diseases